British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

GSK (GSK) stock in focus as the company bid to expand use of oral antibiotic agent gepotidacin for urogenital gonorrhea is granted FDA priority review. Read more here.

Patients with mismatch repair-deficient endometrial cancer have longer overall survival than those with mismatch ...

GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

Harvey Jones takes a look at 2 FTSE 100 income stocks that investors are snubbing right now to see whether there's a big ...

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

More than 600,000 cases of gonorrhoea were reported in the U.S. in 2023, according to the U.S. Centers for Disease Control and Prevention. There are no vaccine licenses in the U.S. for preventing the ...

Drugmaker GSK moved closer to expanding its antibiotic portfolio on Monday, after US regulators accepted its application to review gepotidacin as a potential oral treatment for gonorrhoea.

London’s FTSE 100 confidently opened the week, advancing 0.3%, or 28.30 points, to 9,124.03, supported by gains in Diageo, ...

(Alliance News) - GSK PLC on Monday said its gepotidacin drug has been accepted for priority review in the US as an oral option for the treatment of a form of sexually transmitted infection gonorrhoea ...

OPEN The FTSE 100 was expected to open just 5.8 points higher ahead of the bell after wrapping up the previous session 0.6% lower at 9,095.73.